Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score.

Autor:	Johnson PW; Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL., Kunze KL; Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ., Senefeld JW; Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN., Sinclair JE; Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL., Isha S; Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL., Satashia PH; Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL., Bhakta S; Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL., Cowart JB; Division of Hospital Internal Medicine, Mayo Clinic, Jacksonville, FL., Bosch W; Division of Infectious Diseases, Mayo Clinic, Jacksonville, FL., O'Horo J; Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN.; Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN., Shah SZ; Department of Transplantation, Mayo Clinic, Jacksonville, FL., Wadei HM; Department of Transplantation, Mayo Clinic, Jacksonville, FL., Edwards MA; Department of General Surgery, Mayo Clinic, Jacksonville, FL., Pollock BD; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Jacksonville, FL., Edwards AJ; Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL., Scheitel-Tulledge S; Division of Community Internal Medicine, Geriatrics and Palliative Care, Mayo Clinic, Rochester, MN., Clune CG; Department of Primary Care Internal Medicine, Mayo Clinic, Rochester, MN., Hanson SN; Department of Family Medicine, Mayo Clinic Health Systems, Mankato, MN., Arndt R; Department of Pharmacy, Mayo Clinic Health System, Eau Claire, WI., Heyliger A; Department of Pharmacy, Mayo Clinic, Rochester, MN., Kudrna C; Department of Information Technology, Mayo Clinic, Rochester, MN., Bierle DM; Department of General Internal Medicine, Mayo Clinic, Rochester, MN., Buckmeier JR; Department of Information Technology, Mayo Clinic, Rochester, MN., Seville MTA; Division of Infectious Diseases, Mayo Clinic, Scottsdale, AZ., Orenstein R; Division of Infectious Diseases, Mayo Clinic Arizona, Phoenix, Arizona., Libertin C; Division of Infectious Diseases, Mayo Clinic, Jacksonville, FL., Ganesh R; Department of General Internal Medicine, Mayo Clinic, Rochester, MN., Franco PM; Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL.; Department of Transplantation, Mayo Clinic, Jacksonville, FL.; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Jacksonville, FL., Razonable RR; Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN., Carter RE; Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL., Sanghavi DK; Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL., Speicher LL; Division of General Internal Medicine, Mayo Clinic, Jacksonville, FL.
Jazyk:	angličtina
Zdroj:	Mayo Clinic proceedings. Innovations, quality & outcomes [Mayo Clin Proc Innov Qual Outcomes] 2023 Apr; Vol. 7 (2), pp. 109-121. Date of Electronic Publication: 2023 Jan 11.
DOI:	10.1016/j.mayocpiqo.2022.12.007
Abstrakt:	Objective: To test the hypothesis that the Monoclonal Antibody Screening Score performs consistently better in identifying the need for monoclonal antibody infusion throughout each "wave" of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant predominance during the coronavirus disease 2019 (COVID-19) pandemic and that the infusion of contemporary monoclonal antibody treatments is associated with a lower risk of hospitalization. Patients and Methods: In this retrospective cohort study, we evaluated the efficacy of monoclonal antibody treatment compared with that of no monoclonal antibody treatment in symptomatic adults who tested positive for SARS-CoV-2 regardless of their risk factors for disease progression or vaccination status during different periods of SARS-CoV-2 variant predominance. The primary outcome was hospitalization within 28 days after COVID-19 diagnosis. The study was conducted on patients with a diagnosis of COVID-19 from November 19, 2020, through May 12, 2022. Results: Of the included 118,936 eligible patients, hospitalization within 28 days of COVID-19 diagnosis occurred in 2.52% (456/18,090) of patients who received monoclonal antibody treatment and 6.98% (7,037/100,846) of patients who did not. Treatment with monoclonal antibody therapies was associated with a lower risk of hospitalization when using stratified data analytics, propensity scoring, and regression and machine learning models with and without adjustments for putative confounding variables, such as advanced age and coexisting medical conditions (eg, relative risk, 0.15; 95% CI, 0.14-0.17). Conclusion: Among patients with mild to moderate COVID-19, including those who have been vaccinated, monoclonal antibody treatment was associated with a lower risk of hospital admission during each wave of the COVID-19 pandemic. Competing Interests: Dr O’Horo received grants from nference, Inc, and the MITRE Corporation and consulting fees from Bates College, all of which was outside the present work. Dr Razonable received grants from Roche, Regeneron, and Gilead; received honoraria from Integritas and Medscape; is on the Data Safety Monitoring Board or Advisory Board for Novartis; and has a leadership role in the American Society of Transplantation. (© 2023 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu